Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
Next revisionBoth sides next revision
home:pathogenesis:th1spectrum [02.09.2019] – [A single diagnosis for chronic inflammatory disease] sallieqhome:pathogenesis:th1spectrum [02.10.2019] sallieq
Line 441: Line 441:
  
 A recent survey of Marshall Protocol patients, discussed in [[home:publications:proal_congress_on_autoimmunity_2008|Amy Proal's presentation]] at Congress on Autoimmunity, showed that of those with Hashimoto's thyroiditis, only 8% had been diagnosed with Hashimoto's alone. A recent survey of Marshall Protocol patients, discussed in [[home:publications:proal_congress_on_autoimmunity_2008|Amy Proal's presentation]] at Congress on Autoimmunity, showed that of those with Hashimoto's thyroiditis, only 8% had been diagnosed with Hashimoto's alone.
 +
 +
 +==== Metabolic syndrome ====
 +
 +Impact of 25-hydroxyvitamin D, free and bioavailable fractions of vitamin D, and vitamin D binding protein levels on metabolic syndrome components   (({{pubmed>long:28721141}})) 
 +
 + 
 +===== Intestinal barrier =====
 +
 +Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer.  (({{pubmed>long:    21248165}})) 
 +
 +The two major triggers of zonulin release that have been described so far are bacteria and gliadin. It is well described that many enteric pathogens are able to produce enterotoxins that affect the intestinal tight junction of the host.   (({{pubmed>long:28123927}})) 
 ===== The challenge of diagnosing diseases caused by bacteria ===== ===== The challenge of diagnosing diseases caused by bacteria =====
  
Line 493: Line 505:
  
 A corollary of this principle is that attempts to compare one patient's disease with another's may be futile. Certainly there is a great deal of variability in the location and severity of infection and the corresponding symptoms, but ultimately there is no fundamental difference between the origin of patients' disease states and there is, therefore, no significant difference in their ultimate recovery trajectories.  A corollary of this principle is that attempts to compare one patient's disease with another's may be futile. Certainly there is a great deal of variability in the location and severity of infection and the corresponding symptoms, but ultimately there is no fundamental difference between the origin of patients' disease states and there is, therefore, no significant difference in their ultimate recovery trajectories. 
- 
- 
- 
-==== Metabolic syndrome ==== 
- 
-Impact of 25-hydroxyvitamin D, free and bioavailable fractions of vitamin D, and vitamin D binding protein levels on metabolic syndrome components   (({{pubmed>long:28721141}}))  
- 
- (({{pubmed>long:000}}))  
- 
- (({{pubmed>long:000}}))  
- 
- (({{pubmed>long:000}}))  
- 
- 
- 
-===== Intestinal barrier ===== 
- 
-Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer.  (({{pubmed>long:    21248165}}))  
- 
-The two major triggers of zonulin release that have been described so far are bacteria and gliadin. It is well described that many enteric pathogens are able to produce enterotoxins that affect the intestinal tight junction of the host.   (({{pubmed>long:28123927}}))  
- 
  
  
Line 524: Line 515:
  
 ===== Notes and comments ===== ===== Notes and comments =====
 +
 +
 + (({{pubmed>long:000}})) 
  
 --- //Sallie Q 11.28.2016//removed ~~NOEXPLAIN~~ from start of page edit --- //Sallie Q 11.28.2016//removed ~~NOEXPLAIN~~ from start of page edit
home/pathogenesis/th1spectrum.txt · Last modified: 01.13.2024 by ron
© 2015, Autoimmunity Research Foundation. All Rights Reserved.